Skip to content
Screener

Arrowhead Research ARWR Financing Cash Flow

Financing Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
ALN
Alnylam PharmaceuticalsALNY
$36.24M-32.6%
Assembly Biosciences logo
Assembly BiosciencesASMB
$149K-92.2%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$11.62M+317%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$96.61M-79.6%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemSix Months Ended March 31, 2026Six Months Ended March 31, 2025
Payments of issuance costs of common stock related to follow-on offering(13,393)
Repayments of credit facility(84,506)(151,625)
Dividends paid by variable interest entity to noncontrolling shareholders(41,514)
Net cash provided by financing activities780,967113,016
Net (decrease) increase in cash, cash equivalents and restricted cash(39,134)83,494
Effect of exchange rate on cash, cash equivalents and restricted cash1,103(470)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
BEGINNING OF PERIOD226,548102,685

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's financing cash flow?
Arrowhead Research (ARWR) reported financing cash flow of $795.72M in Q1 2026.
How has Arrowhead Research's financing cash flow changed year-over-year?
Arrowhead Research's financing cash flow increased by 761.3% year-over-year, from $92.38M to $795.72M.
What is the long-term trend for Arrowhead Research's financing cash flow?
Over 3 years (2021 to 2024), Arrowhead Research's financing cash flow has grown at a 325.4% compound annual growth rate (CAGR), from $11.31M to $870.52M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Arrowhead Research's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude